• There are no suggestions because the search field is empty.

Careers    Developers    Support     日本語

Back to Resource Hub Article

Why eCOA Is the Cornerstone of Every Decentralized Trial

Signant Health
Jun 19, 2026
Article
Participant dropout strategies in anti-obesity medication clinical trials

Electronic Clinical Outcome Assessment (eCOA) is the single non-negotiable foundation of any decentralized clinical trial. Writing in International Clinical Trials (February 2023), Bill Byrom PhD, Dan DeBonis, and Anthony Everhart MD of Signant Health identified seven learnings from DCT implementation at scale.  

Their central finding: sponsors who struggled with DCTs often focused on platform architecture before ensuring their eCOA was fit for purpose. 

Why It Matters Now  
 
For participants managing serious illness, every unnecessary site visit carries a cost that goes beyond inconvenience. Travel demands, fatigue, and the fear of missing a dose or a window, compound the burden of the disease itself. Sponsors who underestimate this design their trials around operational convenience rather than participant reality, and adherence suffers as a result. 

The FDA's 2023 draft guidance on decentralized clinical trials signals that regulators now expect sponsors to document how remote modalities preserve measurement validity. That expectation is active now, for trials in design today. Sponsors who treat DCT methodology as an overlay on a standard protocol, rather than as a foundational design decision, will face amendment cycles and data credibility questions that slow regulatory progress. 

What the Evidence Shows       
 
Many sponsors who experienced DCT disillusionment did so because they prioritized single-platform architecture over solution maturity. Byrom, DeBonis, and Everhart, writing from more than 30 years of combined clinical trial technology and scientific experience at Signant Health, argue this is the wrong sequencing.  
 
The question is not whether all components sit within one vendor interface. The question is whether each component, particularly eCOA, is sufficient to meet the protocol without bending the protocol to fit. 
 
Their seven learnings, drawn from clinical practice and published in a peer-reviewed journal, cover methodological continuity from pre-DCT decentralization approaches, the conditions under which integration matters versus when it adds unnecessary complexity, the overlooked role of direct-to-patient drug supply, and the case for reframing DCTs as trial optimization rather than site-visit reduction. Sponsors approaching their next hybrid or fully remote study design will find the full article examines each of these in detail, with named references to published clinical evidence, including Kobak (2004) on videoconference administration of the Hamilton Depression Rating Scale and the Trials@Home research program.  
 
 

"The DCT slope of enlightenment reveals the importance of reliable eCOA as the critical ingredient of successful DCTs. Adding newer decentralized methodologies upon the cornerstone of eCOA will lead to greater and more rapid success." - Bill Byrom, PhD, Principal, eCOA Science, Signant Health 

How does eCOA in a decentralized trial differ from eCOA in a site-based trial?

In a decentralized trial, eCOA must support multiple modalities, provisioned devices, BYOD, and web, while maintaining data quality equivalent to site-based collection. The instrument, edit checks, and compliance monitoring requirements are identical. What changes are the delivery architecture, participant support model, and logistics infrastructure required to sustain adherence remotely?

Do all DCT components need to come from a single technology vendor?

Not necessarily. Byrom, DeBonis, and Everhart (ICT, 2023) conclude that integration matters most where participant workflow is disrupted by switching between modalities. Pre-study consent via web and in-study eCOA via a dedicated app serve different interaction contexts and do not require convergence within a single platform, provided data integrity and audit trails are maintained across components.

What is the most common reason DCT implementations underperform?

The authors identify two primary factors: prioritizing single-platform architecture over solution maturity in individual components, and framing DCTs as site-visit reduction rather than trial optimization. Studies designed to reduce visits without evaluating which activities can be validly migrated to remote settings risk generating data quality problems that surface late in the study.

 
 

AUTHOR BIO 

Name: Bill Byrom, Dan DeBonis, Anthony Everhart
Title and Credentials: Bill Byrom, PhD, Principal, eCOA Science, Signant Health | Dan DeBonis, Principal, Endpoint Solutions, Signant Health | Anthony Everhart, MD, Clinical Vice President, Internal Medicine, Signant Health
Bio: Bill Byrom, PhD, Principal, eCOA Science, Signant Health. Bill Byrom has worked in the pharmaceutical industry for 30 years. He has authored more than 70 publications and two industry textbooks on electronic patient-reported outcomes. His recent work focuses on wearable technology and BYOD eCOA in clinical trials. 

Dan DeBonis, Principal, Endpoint Solutions, Signant Health. Dan DeBonis leads eCOA innovation, outcome analytics, and digital technologies at Signant Health. He holds a patent in clinical research technology and has authored multiple publications in the field. 

Anthony Everhart, MD, Clinical Vice President, Internal Medicine, Signant Health. Anthony Everhart has over 25 years of medical practice experience and 14 years in clinical research. Board-certified in Internal Medicine and a Fellow of the American College of Physicians, he specializes in decentralized trials, rater training, blinded data analytics, and placebo response mitigation.  

 

Designing a hybrid or decentralized study and evaluating your eCOA strategy? Speak to a Signant eCOA expert. 

Explore Our Content

Get notified on new marketing insights

Here mention the benefits of subscribing